Status:
COMPLETED
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisp...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of multiple myeloma
- Have been on zoledronic acid or pamidronate for 1-2 years and therapy must have been initiated for osteolytic lesion, bone fracture, spinal compression, or osteopenia due to multiple myeloma
- Stable renal function
Exclusion
- Known sensitivity to bisphosphonates
- Receiving investigational drugs considered not safe for co-administration or have a significant effect on bone turnover
- Current active dental problems
- Had bone marrow transplant or blood stem cell transplant within 2 months before study entry or planned transplant within 2 months following enrollment
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
November 7 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 3 2012
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00622505
Start Date
November 7 2007
End Date
April 3 2012
Last Update
May 26 2021
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
TriValley Cancer Research and Treatment Center
Casa Grande, Arizona, United States, 85222
2
Wilshire Oncology Medical Group
La Verne, California, United States, 91750
3
Cedars Sinai Medical Center Outpatient Cancer Ctr. (4)
Los Angeles, California, United States, 90048
4
Palo Alto Medical Foundation Hematology/Oncology
Mountain View, California, United States, 94040